The FDA's Overton era, and dispatches from Shanghai

The FDA faces a pivotal transition as nominee Heidi Overton, a preventive medicine physician with deep ties to the Trump administration, navigates the agency's recent staffing losses and internal political turbulence. Simultaneously, the pharmaceutical industry is witnessing a renewed focus on osteoporosis treatments, alongside a significant $1.65 billion merger between ITM and Tealix in the radiopharmaceutical sector. Meanwhile, China has emerged as a global drug discovery powerhouse, now accounting for approximately one-third of the world's drug development pipeline. This rapid expansion, fueled by government support and a surge in STEM graduates, presents both competitive opportunities and geopolitical challenges for U.S. firms. While Chinese biotech companies offer increased efficiency and speed, recent patient safety concerns in investigator-initiated trials underscore the ongoing need for rigorous oversight in this rapidly evolving market.